John Cavan
Chief Executive Officer presso HEPION PHARMACEUTICALS, INC.
Patrimonio netto: 1 860 $ in data 31/03/2024
Posizioni attive di John Cavan
Società | Posizione | Inizio | Fine |
---|---|---|---|
HEPION PHARMACEUTICALS, INC. | Chief Executive Officer | 04/12/2023 | - |
Director of Finance/CFO | 01/01/2016 | - | |
Public Communications Contact | 01/01/2016 | - | |
Vantage Health System, Inc. | Director/Board Member | - | - |
Storia della carriera di John Cavan
Precedenti posizioni note di John Cavan
Società | Posizione | Inizio | Fine |
---|---|---|---|
AEGERION PHARMACEUTICALS, INC. | Comptroller/Controller/Auditor | 16/08/2010 | 01/02/2012 |
STEMLINE THERAPEUTICS, INC. | Comptroller/Controller/Auditor | 01/06/2006 | 01/02/2012 |
AlgoRx Pharmaceuticals, Inc.
AlgoRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AlgoRx Pharmaceuticals, Inc. was a pharmaceutical company. The company developed and commercialized drugs for pain management. The company was founded in 2001 and was hedquartered in Secaucus, NJ. | Comptroller/Controller/Auditor | 01/01/2004 | - |
Formazione di John Cavan
Iona College | Undergraduate Degree |
Seton Hall University | Masters Business Admin |
Statistiche
Distribuzione geografica
Stati Uniti | 8 |
Posizioni
Comptroller/Controller/Auditor | 3 |
Undergraduate Degree | 1 |
Masters Business Admin | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 1 |
---|---|
HEPION PHARMACEUTICALS, INC. | Health Technology |
Aziende private | 4 |
---|---|
Aegerion Pharmaceuticals, Inc.
Aegerion Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aegerion Pharmaceuticals, Inc. operates as a biopharmaceutical company. It engages in the development and commercialization of therapies for patients with debilitating rare diseases. The company was founded by David I. Scheer, Gerald L. Wisler and William H. Lewis in 2005 and is headquartered in Cambridge, MA. | Health Technology |
Stemline Therapeutics, Inc.
Stemline Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Stemline Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery, acquisition, development, and commercialization of novel therapeutics for oncology indications of unmet medical need. Its clinical stage product candidates include SL-401, SL-801, and SL-701. The SL-401, is a targeted therapy directed to the interleukin-3 receptor (CD123) present on a malignancies. The SL-801, is a novel oral small molecule reversible inhibitor of XPO1, that has demonstrated in vivo and in vitro preclinical activity in solid and hematologic malignancies. The SL-701, is an immunotherapy designed to activate the immune system to attack tumors. The company was founded by Ivan Bergstein on August 8, 2003 and is headquartered in New York, NY. | Health Technology |
AlgoRx Pharmaceuticals, Inc.
AlgoRx Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology AlgoRx Pharmaceuticals, Inc. was a pharmaceutical company. The company developed and commercialized drugs for pain management. The company was founded in 2001 and was hedquartered in Secaucus, NJ. | Health Technology |
Vantage Health System, Inc. |
- Borsa valori
- Insiders
- John Cavan
- Esperienza